Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 316 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis C Patients Clear all

Conditions: Hepatitis C, Chronic
Interventions: PegIFN/RBV, BI201335, BI201335 24W, Bi 201335; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 22
States / cities: Birmingham, Alabama • Palm Springs, California • San Francisco, California + 17 more

Conditions: Alcohol Use Disorder, HIV/AIDS, Hepatitis C, Binge Drinking
Interventions: Intervention: (Clinician's Guide + HealthCall for HIV/HCV); Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Hemodialysis, Nosocomial Infection
Interventions: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatitis C, Chronic
Interventions: RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 15
States / cities: Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more

Conditions: Hepatitis C
Interventions: Use of Tappt App; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatitis C
Interventions: Sofosbuvir, Placebo, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Immunosuppressant Regimen; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more

Conditions: Hepatitis C, Chronic
Interventions: BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 31
States / cities: North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more

Conditions: End Stage Renal Disease, Chronic Hepatitis c
Interventions: Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 34 Years to 44 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C
Interventions: Data-assisted Case Navigation, Standard of Care; Behavioral
Lead sponsor: National Opinion Research Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, Placebo, RO5190591 (Danoprevir); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more

Conditions: Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
Interventions: Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 11
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Healthy Volunteers, Hepatitis C Virus
Interventions: RO5024048; Drug
Lead sponsor: Pharmasset; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more

Conditions: Chronic Hepatitis C
Interventions: valopicitabine, pegylated interferon; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Timeline: Started 2004
U.S. locations: 2
States / cities: Bradenton, Florida • San Antonio, Texas

Conditions: Hepatitis C
Interventions: Interleukin 28B genotype; Genetic
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HIV Infections, Hepatitis C
Interventions: Silymarin, Placebo; Drug
Lead sponsor: Henry Sacks; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Depression
Interventions: Citalopram or Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Hepatitis C
Interventions: Taribavirin, Ribavirin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatitis C, Chronic
Interventions: Pegylated-interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 11
States / cities: Sacramento, California • San Francisco, California • Lutherville, Maryland + 8 more

Conditions: Hepatitis C, Chronic
Interventions: Previous treatment in DEB025 study; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: San Diego, California • Ventura, California • Honolulu, Hawaii + 4 more

Conditions: Hepatitis C, Chronic
Interventions: ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 24
States / cities: La Jolla, California • Long Beach, California • San Diego, California + 20 more

Conditions: Hepatitis C, Chronic Pain
Interventions: Alisporivir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 16
States / cities: La Jolla, California • San Diego, California • Ventura, California + 9 more

Conditions: Cirrhosis
Interventions: Not listed
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Drug Use, HIV, Hepatitis C
Interventions: Brief motivational intervention; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV

Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

HCV Tappt Adherence Study

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

Registry-based HCV Care Cascade Navigation at Atlanta's Grady Memorial Hospital

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B

A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C

VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients

Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

Increasing Viral Testing in the Emergency Department